Click For Photo: http://i.dailymail.co.uk/i/pix/2016/06/10/21/3523974000000578-0-image-a-24_1465591652412.jpg
A new drug could offer hope to people across the world living with the painful skin condition, psoriasis.
A new study has shown ixekizumab completely or almost completely cleared the disease in 80 per cent of patients with moderate to severe psoriasis.
The findings from three large, long-term clinical trials, are published in the New England Journal of Medicine.
Dr Kenneth Gordon, professor of dermatology at Northwestern University and first author of the paper, said: 'This group of studies not only shows very high and consistent levels of safety and efficacy, but also that the great majority of the responses persist persist at least 60 weeks.'
Psoriasis, which affects around three per cent of the world's population, is an immune-mediated inflammatory disease that causes itchy, dry and red skin.
It is also linked to an increased risk for depression, heart disease and diabetes, among other conditions.
Ixekizumab works by neutralizing a pathway in the immune system known to promote psoriasis.
To test the drug's efficacy over time - and to help clinicians determine whether its benefits outweigh any risks - the three studies enrolled a total of 3,736 adult patients at more than 100 study sites across 21 countries.
All participants had moderate to severe psoriasis, which is defined as covering 10 per cent or more of the body.
Patients were randomly assigned...
Wake Up To Breaking News!
The American Government, working tireless for everyone, except Americans.